ALK and non-small cell lung carcinoma: In light of the ALINA trial findings, alectinib has been approved by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) as adjuvant therapy for patients with stage IB–IIIA ALK-positive NSCLC following curative resection.